Cumulative Index

February–May

Page numbers of clinic titles are given in **boldface** type.

ABNORMALITIES
  chromosomal, genetic counseling in, *May*, 349
  congenital
    due to rubella, *May*, 258, 259
      frequency, *May*, 252
    genetic counseling in, *May*, 348, 349
  cytogenetic, in leukemia, *May*, 274
Abortion, therapeutic, in rubella, *May*, 261
Accelerated reaction to smallpox vaccination, *Feb.*, 91
Acid. See specific acids, as *Homovanillic acid*, etc.
Acidification of urine, *May*, 240
Acidosis. See also *Alkalosis.*
  lactic
    clinical features, *May*, 496
    infantile, familial, *May*, 491
      clinical features, *May*, 496
    with necrotizing encephalopathy, *May*, 491
ACTH. See *Corticotropin.*
Actinomycin C after renal transplantation, *May*, 393, 394
Adrenal glands. See also *Corticotropin.*
  cortex, insufficiency, after surgery for pheochromocytoma, *Feb.*, 16
  fetal
    corticosteroid content, *Feb.*, 61
    histochemical studies, *Feb.*, 63
    regulation, *Feb.*, 64–7
    steroid biosynthesis in, *Feb.*, 59–64
    studies in vitro, *Feb.*, 61–3
  hormones, and growth hormone, *May*, 447–8
Adrenalectomy for primary hyperaldosteronism, *Feb.*, 51
Adrenocortical insufficiency after surgery for pheochromocytoma, *Feb.*, 16
Adrenocorticosteroids for neural tumors with chronic diarrhea, *Feb.*, 13
Adrenogenital syndrome
  due to 3-beta-hydroxysteroid dehydrogenase deficiency, *May*, 489–90
    clinical features, *May*, 496
Age incidence of lymphocytic thyroiditis, *Feb.*, 26
Albinism, genetics, *May*, 339
Aldosterone, *Feb.*, 43
  escape in hyperaldosteronism, *Feb.*, 50
  excretion, *Feb.*, 44
  production, *Feb.*, 44
  regulation, *Feb.*, 44–7
  secretion, *Feb.*, 44, 45, 46
    decreased, diseases with, *Feb.*, 54–6
    disorders of, *Feb.*, 43–58
    increased, diseases with, *Feb.*, 47–54
Aldosteronism, congenital, *Feb.*, 48
Alkalosis. See also *Acidosis.*
  hypokalemic, and hypertension with hypoaldosteronism, *Feb.*, 53
Alleles, *May*, 339
Allergic reactions to smallpox vaccination, *Feb.*, 91–2
Amino acids. See also *Proteins;* and specific acids, as *Lysine;* etc.
  metabolism in homocystinuria, *May*, 472
Ammonia intoxication, periodic. See under *Lysine intolerance.*
Ampicillin
  therapeutic use, *May*, 244, 245
    in newborn, *May*, 538
Anemia, hemolytic
  in hemolytic-uremic syndrome, *May*, 298, 299
    pathophysiology, *May*, 304–306
Anencephalic infant, steroids in, *Feb.*, 65
Anomalous pulmonary venous drainage, total, *Feb.*, 178–87
Antibiotics. See also specific drugs, as *Penicillin;* etc.
  for neuroblastoma, *Feb.*, 11
  therapy, 1966, *May*, 231–50
Antibodies
  autoantibodies, thyroid, detection of, *Feb.*, 30
  response
    to immunization, factors influencing, *Feb.*, 77–9
    to poliovirus, *Feb.*, 94

Antibodies (*Continued*)
thyroid, in lymphocytic thyroiditis, *Feb.*, 31
Antimetabolites
for neuroblastoma, *Feb.*, 11
in rubella, *May*, 262
Antimicrobials. See *Antibiotics; Drugs.*
Antitoxin, tetanus, *Feb.*, 87, 88
Aorta, coarctation, *Feb.*, 128–37
Aortic stenosis, congenital, *Feb.*, 118–27
Ascorbic acid for acidification of urine, *May*, 240
Asthmatics, metyrapone test in, *May*, 547, 551
Atresia, tricuspid, *Feb.*, 208–17
Atrial septal defect, *Feb.*, 148–57
ostium primum, *Feb.*, 168
secundum type, *Feb.*, 148–57
Atrioventricular canal defects, *Feb.*, 168–77
Autoantibodies, thyroid, detection of, *Feb.*, 30
Autoimmunity, thyroid, in lymphocytic thyroiditis, *Feb.*, 22–5
Autosomal inheritance. See under *Inheritance.*
Azathioprine (Imuran)
after renal transplantation, *May*, 391
toxicity after renal transplantation, *May*, 396–7

BACITRACIN
dosage, *May*, 233
therapeutic use, *May*, 232–3
in newborn, *May*, 535
Bartter's syndrome, *Feb.*, 53
Behavior
delinquent, *May*, 459–68. See also *Delinquency.*
genetic factors in, *May*, 373–7
nutritional factors in, *May*, 373–7
sex differences in, *May*, 377
BEI. See *Iodine, butanol-extractable.*
BGH. See *Growth hormone, bovine.*
Bioassays of somatotropin, *May*, 440
Biopsy findings in lymphocytic thyroiditis, *Feb.*, 31, 32
Biosynthesis, steroid, in fetal adrenal, *Feb.*, 59–64
Bleeding. See *Hemorrhage.*
Blood. See also *Anemia.*
groups in organ transplantation, *May*, 383
in hemolytic-uremic syndrome, *May*, 298–300
pressure. See also *Hypertension.*
in pheochromocytoma, *Feb.*, 14
transfusion for anemia in hemolytic-uremic syndrome, *May*, 306
Blood vessels. See also *Aorta; Capillaries.*
great, transposition of, *Feb.*, 198–207
Blue diaper syndrome, *May*, 478
clinical features, *May*, 494
Body
length
parent-child correlations, *May*, 355
sibling correlations, *May*, 354
size, genetic and nutritional factors, *May*, 353–60
Bovine growth hormone, *May*, 448
Brain. See also *Hypothalamus; Nervous system;* etc.
involvement in homocystinuria, *May*, 471

CALCIUM
metabolism, effect of somatotropin on, *May*, 446
restriction in hypercalcemia, *May*, 516
serum, in hypercalcemia, *May*, 510
Canal, atrioventricular, defects of, *Feb.*, 168–77
Capillaries. See also *Blood vessels.*
glomerular, fibrin thrombosis of, in hemolytic-uremic syndrome, *May*, 301
Carbohydrate metabolism, effect of somatotropin on, *May*, 446
Carcinoma of thyroid, *Feb.*, 19
Cardiac. See *Heart.*
Cardiovascular lesions in hypercalcemia, *May*, 511–13
Catecholamines, *Feb.* 3–4
excretion
in neural tumors with chronic diarrhea, *Feb.*, 13
in neuroblastoma, *Feb.*, 8, 11
in pheochromocytoma, *Feb.*, 15
metabolism in neuroblastoma, *Feb.*, 9
Cells, reticulum, sarcoma, vs. neuroblastoma, *Feb.*, 7
Central nervous system, effects of cytomegalovirus infection on, *May*, 283–5
Cephalothin (Keflin)
dosage, *May*, 234
therapeutic use, *May*, 233–4
Chemicals, leukemia due to, *May*, 270
Chemotherapy
for ganglioneuroblastoma, *Feb.*, 12
for neuroblastoma, *Feb.*, 9, 10, 11
Child-rearing, defects in, delinquency due to, *May*, 463–6
Chloramphenicol
dosage, *May*, 236
therapeutic use, *May*, 234–6
in newborn, *May*, 535
Choreo-athetosis, mental deficiency and self-mutilation, hyperuricemia with, *May*, 486, 495

Chromosomes. See also *Genetics; Heredity.*
abnormalities, genetic counseling in, *May,* 349
normal number, *May,* 338
Citrullinemia, *May,* 485–6
clinical features, *May,* 495
Clinical advances, recent, symposium on, *May,* **229–541**
Clonal selection theory, *Feb.,* 23
Cloxacillin (Tego Pen), therapeutic use, *May,* 242, 243
Coarctation of aorta, *Feb.,* 128–37
Colistimethate
therapeutic use, *May,* 245, 246
in newborn, *May,* 536
Colistin. See *Colistimethate.*
Colon, malrotation, congenital, genetic counseling in, *May,* 346
Congenital abnormalities due to rubella, *May,* 258, 259
Congenital aortic stenosis, *Feb.,* 118–27
Congenital defects due to rubella, frequency, *May,* 252
Congenital heart disease, operable, *Feb.,* **105–219**
Cord, umbilical. See *Umbilical cord.*
Corticosteroids
biosynthesis in fetal adrenal, *Feb.,* 59–64
conversions in fetal adrenal, *Feb.,* 61
fetal, role of, *Feb.,* 67–8
for neural tumors with chronic diarrhea, *Feb.,* 13
for neuroblastoma, *Feb.,* 11
in anencephalic infant, *Feb.,* 65
in cytomegalovirus infection, *May,* 290
in fetal adrenals, *Feb.,* 61
in umbilical cord plasma, measurement, *Feb.,* 63–4
labeled, perfusion of fetus, *Feb.,* 64
maternal, placental transport of, *Feb.,* 68–9
Corticotropin (ACTH)-cortisol insufficiency
avoidance of, *May,* 553–5
iatrogenic, duration of, *May,* **543–57**
Cortisol. See *Hydrocortisone.*
Cortisone in hypercalcemia, *May,* 517
Counseling, genetic, *May,* 337–52
Craniosynostosis in hypercalcemia, *May,* 509
Creatinine, urinary, in ACTH-cortisol insufficiency, *May,* 545
Cyclophosphamide for neuroblastoma, *Feb.,* 11
Cystathionine metabolism in homocystinuria, *May,* 471
Cystinlysinuria, *May,* 486
Cytogenetic abnormalities in leukemia, *May,* 274
Cytomegalic inclusion disease, *May,* 279
etiology, *May,* 280–81
Cytomegaloviruses. See under *Viruses.*

DEAFNESS, congenital, genetic causes, *May,* 344
Death after renal transplantation, causes of, *May,* 396
Defects. See *Abnormalities.*
Delinquency, *May,* 459–68
as manifestation of psychotic illness, *May,* 466–7
as response to physical handicap, *May,* 462–3
extent of problem, *May,* 459–60
gang, *May,* 460–61
individual, *May,* 461–7
resulting from defects in rearing process, *May,* 463–6
resulting from developmental retardation, *May,* 461–2
sociologic, *May,* 460–61
types, *May,* 460–67
Delinquent behavior, *May,* **459–68.** See also *Delinquency.*
Dental. See *Teeth.*
Dermatitis as contraindication to smallpox vaccination, *Feb.,* 92
Desoxycorticosterone (DOC) for hypoaldosteronism, *Feb.,* 56
Development. See also *Growth.*
behavioral, genetic and nutritional factors in, *May,* 373–7
dental, genetic and nutritional factors, *May,* 367–73
growth and, interaction of nutrition and genetics in timing of, *May,* 353–79
retardation in, delinquency due to, *May,* 461–2
skeletal. See under *Skeleton.*
Dextran in hemolytic-uremic syndrome, *May,* 307
Diabetes mellitus with thyroditis, *Feb.,* 32
Diagnosis in genetic counseling, *May,* 343–6
Dialysis, peritoneal, in hemolytic-uremic syndrome, *May,* 306
Diaper, blue, syndrome of. See *Blue diaper syndrome.*
Diarrhea, chronic, neural tumors and, *Feb.,* 13
Dicloxacillin, therapeutic use, *May,* 243
Diet. See also *Nutrition.*
in hypercalcemia, *May,* 516–17
Dihydroxy-phenylalanine (DOPA) excretion, *May,* 479–80
clinical features, *May,* 494

Diphenicillin, therapeutic use, *May*, 243
Diphtheria immunization, *Feb.*, 81, 84–6
Disease. See also *Death; Diagnosis; Health;* etc.
  cytomegalic inclusion. See *Cytomegalic inclusion disease.*
  determinants, *May*, 316–18
  etiology, psychologic factors in, *May*, 318–20
  genetic, before onset of leukemia, *May*, 272–3
  Hartnup. See *Hartnup disease.*
  Hashimoto's, *Feb.*, 19, 20, 32
  heart. See under *Heart.*
  infectious. See *Infectious disease.*
  oasthouse urine, *May*, 473
  psychogenic, *May*, 319
  Quervain's, *Feb.*, 20
  with decreased aldosterone secretion, *Feb.*, 54–6
  with increased aldosterone secretion, Feb., 47–54
Disorders
  genetic. See *Genetic disorders.*
  of aldosterone secretion, *Feb.*, 43–58
Diuresis after renal transplantation, *May*, 391
DOC. See *Desoxycorticosterone.*
Donor selection for renal transplantation, *May*, 383–5
DOPA. See *Dihydroxy-phenylalanine.*
Dopamine, *Feb.*, 3, 4
  excretion
    in neuroblastoma, *Feb.*, 9
    in pheochromocytoma, *Feb.*, 15
Down's syndrome, leukemia and, *May*, 272
Drainage, pulmonary venous, anomalous, total, *Feb.*, 178–87
Drugs. See also names of drugs.
  absorption in newborn, *May*, 528–9
  distribution in newborn, *May*, 529–31
  dosage for newborn, *May*, 534, 535
  excretion in newborn, *May*, 533–4
  metabolism in newborn, *May*, 531–3
  protein binding, *May*, 530
Ductus arteriosus, patent, *Feb.*, 138–47
Dwarfism
  congenital tryptophanuria with, *May*, 478
  pituitary, somatotropin for, *May*, 449, 450
Dystrophy, muscular, *May*, 492–3
  clinical features, *May*, 496

Eczema
  as contraindication to smallpox vaccination, *Feb.*, 92
  vaccinatum, *Feb.*, 93
Elbow, skeletal development, *May*, 366
Electrocardiogram
  in aortic stenosis, *Feb.*, 121
  in atrial septal defect, *Feb.*, 151
  in coarctation of aorta, *Feb.*, 131
  in endocardial cushion defects, *Feb.*, 171
  in patent ductus arteriosus, *Feb.*, 141
  in pulmonic stenosis, *Feb.*, 111
  in tetralogy of Fallot, *Feb.*, 191
  in transposition of great vessels, *Feb.*, 201
  in transposition of pulmonary veins, *Feb.*, 181
  in tricuspid atresia, *Feb.*, 211
  in ventricular septal defect, *Feb.*, 161
Elfin facies in hypercalcemia, *May*, 507
Embryopathy, rubella, prophylaxis of, *May*, 260–63
Encephalitis, postvaccinal, *Feb.*, 93
Encephalopathy, necrotizing, lactic acidosis with, *May*, 491, 496
Endocardial cushion defects, *Feb.*, 168–77
Endocrine relations, fetal-placental, *Feb.*, 67–9
Enzymes
  in drug metabolism, *May*, 532
  induction in newborn, *May*, 533
Epinephrine, *Feb.*, 3, 4
  excretion in pheochromocytoma, *Feb.*, 15
Erythrocytes. See also *Anemia.*
  in hemolytic-uremic syndrome, *May*, 299
Erythromycin
  therapeutic use, *May*, 236
    in newborn, *May*, 536
Estriol excretion as index of fetal viability, *Feb.*, 68
Estrogens
  estriol excretion as index of fetal viability, *Feb.*, 68
  production, fetal role in, *Feb.*, 67
Ethical issues in renal transplantation, *May*, 386–7
Euthyroid child, goiter in, *Feb.*, 26
Ewing's tumor vs. neuroblastoma, *Feb.*, 7
Exanthems, viral, glucocorticoid therapy during, *May*, 555
Eyes, involvement in homocystinuria, *May*, 471

ECTOPIA lentis in homocystinuria, *May*, 469, 471

FACIES, elfin, in hypercalcemia, *May*, 507
Fallot, tetralogy of, *Feb.*, 188–97
Familial hypolipidemia, *May*, 478

Familial infantile lactic acidosis. See under *Acidosis.*
Family history in genetic disorders, *May,* 344–5
Fetal-placental endocrine relations, *Feb.,* 67–9
Fetal-placental-maternal interrelations involving steroid hormones, *Feb.,* **59–73**
Fetus. See also *Newborn; Placenta; Umbilical cord;* etc.
  adrenal glands. See *Adrenal glands, fetal.*
  coarctation of aorta, *Feb.,* 129, 131
  perfusion with labeled steroids, *Feb.,* 64
  risk of rubella to, *May,* 251–2
  steroids, role of, *Feb.,* 67–8
  viability, estriol excretion as index of, *Feb.,* 68
Fibrin thrombosis of glomerular capillaries in hemolytic-uremic syndrome, *May,* 301
Fibroplasia, retrolental, genetic counseling in, *May,* 347
Fluid therapy, parenteral, in chronic diarrhea with neural tumor, *Feb.,* 13
Fluoride in lactic acidosis with necrotizing encephalopathy, *May,* 491
Fluorohydrocortisone for hypoaldosteronism, *Feb.,* 56
Foot, skeletal development, *May,* 366
Formiminotransferase deficiency syndrome, *May,* 490–91
  clinical features, *May,* 496
Formula, meat-base, in hypercalcemia, *May,* 516
Furadantin. See *Nitrofurantoin.*

GAMMA globulin
  for measles vaccination, *Feb.,* 99
  immune, for vaccinia, *Feb.,* 92
  in rubella, *May,* 260–61
  tetanus, *Feb.,* 88, 89
Gang delinquency, *May,* 460–61
Ganglioneuroblastoma, *Feb.,* 12
Ganglioneuroma, *Feb.,* 12
Genes, *May,* 339
  dominance vs. recessivity, *May,* 339–41
  incomplete dominance, *May,* 341
  strength, *May,* 339–41
Genetic counseling, *May,* **337–52**
  diagnosis in, *May,* 343–6
Genetic disorders
  etiology, *May,* 344, 345–6
  family history, *May,* 344–5
Genetics. See also *Chromosomes; Heredity.*
  and nutrition, interaction of, in timing of growth and development, *May,* **353–79**
Genetics (*Continued*)
  leukemia and, *May,* 272–4
  problems, *May,* 343
Genotype, *May,* 339
Glands, adrenal. See *Adrenal glands.*
Globulin, gamma. See *Gamma globulin.*
Glomeruli, capillaries, fibrin thrombosis of, in hemolytic-uremic syndrome, *May,* 301
Glomerulonephritis. See *Nephritis, glomerular.*
Glucocorticoids
  ACTH-cortisol insufficiency due to, *May,* 544–5, 547, 552
  postoperative use in primary hyperaldosteronism, *Feb.,* 51
  therapy
    duration, *May,* 555
    during viral exanthems, *May,* 555
    effect on symptoms of disease, *May,* 554
    in stress, *May,* 555
    intermittent, *May,* 553
    tapering, *May,* 553–4
    topical, *May,* 555
    with ACTH therapy, *May,* 553
Glycinemia
  clinical features, *May,* 494
  with hypo-oxaluria, clinical features, *May,* 494
Goiter. See also *Thyroid.*
  in euthyroid child, *Feb.,* 26
  in lymphocytic thyroiditis, *Feb.,* 26–7
Gonadal steroids, role in growth and sexual function, *May,* 432–3
Gonadotropin secretion, control of, *May,* 427–8
Gray syndrome, *May,* 235, 535
Great vessels, transposition, *Feb.,* 198–207
Growth. See also *Development; Diet; Dwarfism; Nutrition;* etc.
  and development, interaction of nutrition and genetics in timing of, *May,* **353–79**
  effect of somatotropin on, *May,* 444–5
  failure, somatotropin for, *May,* 451
  hormone. See *Somatotropin.*
    bovine, *May,* 448
  neuroendocrine regulation, *May,* 423–36
  promotion, protein synthesis in, *May,* 445

HAND, skeletal development, *May,* 366
Handicap, physical, delinquency due to, *May,* 462–3
Hartnup disease, *May,* 476–7
  clinical features, *May,* 494
Hashimoto's disease, *Feb.,* 19, 20, 32

Health. See also *Disease.*
public, considerations in hypercalcemia, *May,* 522–3
Heart
catheterization
in aortic stenosis, *Feb.,* 124
in atrial septal defect, *Feb.,* 154
in coarctation of aorta, *Feb.,* 134
in endocardial cushion defects, *Feb.,* 174
in patent ductus arteriosus, *Feb.,* 144
in pulmonic stenosis, *Feb.,* 114
in tetralogy of Fallot, *Feb.,* 194
in transposition of great vessels, *Feb.,* 204
in transposition of pulmonary veins, *Feb.,* 184
in tricuspid atresia, *Feb.,* 214
in ventricular septal defect, *Feb.,* 164
disease, congenital
clinical classification, *Feb.,* 218
operable, *Feb.,* **105–219**
physiologic classification, *Feb.,* 218
murmur in hypercalcemia, *May,* 509, 511
Height, parent-specific standards, *May,* 357, 358
Hemolytic anemia. See under *Anemia.*
Hemolytic-uremic syndrome, *May,* **295–314**
clinical manifestations, *May,* 297–300
course, *May,* 300–301
history, *May,* 295–7
pathology, *May,* 301–302
pathophysiology, *May,* 302–304
treatment, *May,* 306–307
Hemophilia A, genetics, *May,* 342
Hemorrhage in hemolytic-uremic syndrome, *May,* 300
Heparin
for tissue preservation in renal transplantation, *May,* 387
in hemolytic-uremic syndrome, *May,* 307
Hepatic. See *Liver.*
Herd immunity, *Feb.,* 95
Heredity. See also *Chromosomes; Genetics;* etc.
autosomal, *May,* 341–2
vs. sex-linked, *May,* 341–3
genetic problem, *May,* 343
in lymphocytic thyroiditis, *Feb.,* 33
physical basis, *May,* 338–41
sex-linked, *May,* 342–3
Hetacillin, therapeutic use, *May,* 245
HGH. See *Somatotropin.*
Hip, skeletal development, *May,* 366
Histochemical studies on fetal adrenal tissue, *Feb.,* 63
Histocompatibility tests in renal transplantation, *May,* 385–6
History
family, in genetic disorders, *May,* 344–5
in aortic stenosis, *Feb.,* 120
in atrial septal defect, *Feb.,* 150
in coarctation of aorta, *Feb.,* 130
in endocardial cushion defects, *Feb.,* 170
in patent ductus arteriosus, *Feb.,* 140
in pulmonic stenosis, *Feb.,* 110
in tetralogy of Fallot, *Feb.,* 190
in transposition of great vessels, *Feb.,* 200
in transposition of pulmonary veins, *Feb.,* 180
in tricuspid atresia, *Feb.,* 210
in ventricular septal defect, *Feb.,* 160
Homocystinuria, *May,* 469–72
clinical features, *May,* 494
Homovanillic acid, *Feb.,* 4
excretion
in neuroblastoma, *Feb.,* 9
in pheochromocytoma, *Feb.,* 15
Hormones
growth. See *Somatotropin.*
steroid, fetal-placental-maternal interrelations involving, *Feb.,* 59–73
thyroid, role in growth and sexual function, *May,* 433
HVA. See *Homovanillic acid.*
Hurler's syndrome, genetic causes, *May,* 344
Hydrocortisone (cortisol), *Feb.,* 44
biosynthesis, *Feb.,* 61
for adrenocortical insufficiency after surgery for pheochromocytoma, *Feb.,* 16
for hypoaldosteronism, *Feb.,* 56
Hydrocortisone-ACTH insufficiency, iatrogenic, duration of, *May,* **543–57**
Hydroxycorticosteroids, urinary, in ACTH-cortisol insufficiency, *May,* 545–6, 547
Hydroxykynureninuria, *May,* 479
clinical features, *May,* 494
Hydroxyprolinemia, *May,* 487–8
clinical features, *May,* 495
Hydroxysteroid dehydrogenase deficiency, adrenogenital syndrome due to, *May,* 489–90
Hyperaldosteronism
classification, *Feb.,* 47
juvenile, *Feb.,* 48
primary, *Feb.,* 47–51
vs. secondary hyperaldosteronism, *Feb.,* 52, 53
secondary, *Feb.,* 51–3
vs. primary hyperaldosteronism, *Feb.,* 50, 51
symptoms and signs, *Feb.,* 49

Hyperammoniemia, *May*, 485
Hypercalcemia, infantile, *May*, **503–25**
cardiovascular lesions, *May*, 511–13
clinical features, *May*, 504–509
historical aspects, *May*, 503–504
incidence, *May*, 521–2
laboratory findings, *May*, 509–10
mild, *May*, 504–506
pathogenesis, *May*, 517–21
prognosis, *May*, 515–16
public health considerations, *May*, 522–3
radiographic findings, *May*, 510–11
severe, *May*, 506–509
late normocalcemic stage, *May*, 513–15
terminology, *May*, 503–504
treatment, *May*, 516–17
Hyperglycinemia, *May*, 474–5
with hypo-oxaluria, *May*, 474–5
Hyperlysinemia, *May*, 483–4
clinical features, *May*, 495
Hypermethioninemia, *May*, 472–3
clinical features, *May*, 494
Hyperplasia, thyroid, in lymphocytic thyroiditis, *Feb.*, 21
Hyperprolinemia, *May*, 486–7
Hypersarcosinemia, *May*, 475–6
Hypertension. See also *Blood pressure.*
and hypokalemic alkalosis with hypoaldosteronism, *Feb.*, 53
in pheochromocytoma, *Feb.*, 14
Hyperuricemia with choreo-athetosis, mental deficiency and self-mutilation, *May*, 486
clinical features, *May*, 495
Hypervalinemia, *May*, 483
clinical features, *May*, 495
Hypoaldosteronism, *Feb.*, 54, 55
hypokalemic alkalosis and hypertension with, *Feb.*, 53
treatment, *Feb.*, 56
Hypoglycemia
effect on somatotropin secretion, *May*, 439
somatotropin for, *May*, 451–2
Hypokalemic alkalosis and hypertension with hypoaldosteronism, *Feb.*, 53
Hypolipidemia, familial, *May*, 478
Hypo-oxaluria, hyperglycinemia with, *May*, 474–5
clinical features, *May*, 494
Hypothalamic-pituitary unit, function, *May*, 428–32
Hypothalamus, *May*, 428, 429
role in growth hormone secretion, *May*, 434
role in precocious puberty, *May*, 426–7
Hypothyroidism, *Feb.*, 25
IATROGENIC ACTH-cortisol insufficiency, duration, *May*, **543–57**
Immaturity, immunologic, *Feb.*, 78
Immunity. See also *Antibodies.*
autoimmunity, thyroid, in lymphocytic thyroiditis, *Feb.*, 22–5
durable, due to poliovirus vaccine, *Feb.*, 97
herd, *Feb.*, 95
to poliomyelitis, rapidity after vaccination, *Feb.*, 94–5
Immunization, *Feb.*, 75–104
active, schedule for, *Feb.*, 79–99
antibody response to, *Feb.*, 77–9
current concepts, *Feb.*, **75–104**
diphtheria, *Feb.*, 81, 84–6
general considerations, *Feb.*, 77–9
measles, *Feb.*, 81, 98–9
passive, *Feb.*, 77
pertussis, *Feb.*, 81, 82–4
poliomyelitis, *Feb.*, 81, 93–8, 99–102
rubella, *May*, 262
smallpox, *Feb.*, 81, 89–93
tetanus, *Feb.*, 81, 86–9
Immunoassays of somatotropin, *May*, 440–42
Immunologic considerations, general, *Feb.*, 77–9
Immunologic immaturity, *Feb.*, 78
Immunologic properties of somatotropin, *May*, 442–4
Immunologic tolerance, *Feb.*, 22, 23
Immunosuppression after renal transplantation, *May*, 391–4
rejection after, *May*, 394
Impetigo as contraindication to smallpox vaccination, *Feb.*, 92
Imuran. See *Azathioprine.*
Inborn errors of metabolism. See under *Metabolism.*
Infant, anencephalic, steroids in, *Feb.*, 65
Infantile coarctation of aorta, *Feb.*, 129
Infantile hypercalcemia, *May*, **503–25**
Infantile lactic acidosis, familial. See under *Acidosis.*
Infection. See also *Immunity.*
cytomegalovirus. See *Cytomegalovirus infection.*
rubella, transplacental, *May*, 255–8
Infectious diseases
psychologic factors and resistance to, *May*, **315–35**
clinical studies, *May*, 323–6
experimental studies, *May*, 326–32
Inheritance. See *Heredity.*
Insulin, growth hormone and, *May*, 448
Interaction of nutrition and genetics in timing of growth and development, *May*, **353–79**

Interferon in resistance to viral infections, *May*, 317
Iodine. See also *Goiter; Thyroid.*
  butanol-extractable, in lymphocytic thyroiditis, *Feb.*, 28, 29
  protein-bound, in lymphocytic thyroiditis, *Feb.*, 28, 29
Irradiation. See *Radiation.*
Isolated pulmonic stenosis, *Feb.*, 108–17

KANAMYCIN
  therapeutic use, *May*, 237–8
    in newborn, *May*, 536–7
Keflin. See *Cephalothin.*
Kidneys
  effect of somatotropin on, *May*, 447
  function
    after renal transplantation, *May*, 400
    in drug excretion in newborn, *May*, 533, 534
    in hemolytic-uremic syndrome, *May*, 298
  necrosis, cortical, in hemolytic-uremic syndrome, *May*, 301
  transplantation, *May*, 382–405
    azathioprine toxicity, *May*, 396–7
    death, causes of, *May*, 396
    donor selection, *May*, 383–5
    ethical issues, *May*, 386–7
    histocompatibility tests, *May*, 385–6
    immunosuppression, *May*, 391–4
    mortality after, *May*, 400
    pathologic studies, *May*, 400–405
    pediatric problems, *May*, 397–9
    postoperative care, *May*, 391
    rehabilitation after, *May*, 400
    rejection
      late, *May*, 396
      with immunosuppression, *May*, 394
    renal function after, *May*, 400
    splenectomy, *May*, 399
    survival after, *May*, 400
    technical problems, *May*, 388–91
    thymectomy, *May*, 399
    tissue preservation, *May*, 387–8
  tubular reabsorption of sodium, defect in, *Feb.*, 54
  Wilms's tumor, vs. neuroblastoma, *Feb.*, 7
Knee, skeletal development, *May*, 366

LABORATORY
  data
    in aortic stenosis, *Feb.*, 121–4
Laboratory (*Continued*)
  data
    in atrial septal defect, *Feb.*, 151–4
    in coarctation of aorta, *Feb.*, 131–4
    in endocardial cushion defects, *Feb.*, 171–4
    in lymphocytic thyroiditis, *Feb.*, 28–30
    in patent ductus arteriosus, *Feb.*, 141–4
    in pulmonic stenosis, *Feb.*, 111–14
    in tetralogy of Fallot, *Feb.*, 191–4
    in transposition of great vessels, *Feb.*, 201–204
    in transposition of pulmonary veins, *Feb.*, 181–4
    in tricuspid atresia, *Feb.*, 211–14
    in ventricular septal defect, *Feb.*, 161–4
  findings in hypercalcemia, *May*, 509–10
Lactic acidosis. See under *Acidosis.*
Lactogen, placental, *May*, 449
Leukemia
  cytogenetic abnormalities in, *May*, 274
  etiology, epidemiologic evidence, *May*, 267–77
  genetic disease before onset of, *May*, 272–3
  in twins, concordance rates, *May*, 273
Leukocytes in hemolytic-uremic syndrome, *May*, 300
Leukodystrophy, metachromatic, *May*, 488
  clinical features, *May*, 495
Lincocin. See *Lincomycin.*
Lincomycin (Lincocin), therapeutic use, *May*, 238
Lipid metabolism, effect of somatotropin on, *May*, 446–7
Lipidosis, sulfatide. See *Leukodystrophy, metachromatic.*
Liver transplantation, *May*, 405–19
  auxiliary, *May*, 412–19
  orthotopic, *May*, 405–12
Lymphocytic thyroiditis. See under *Thyroiditis.*
Lysine intolerance, congenital, with periodic ammonia intoxication, *May*, 484
  clinical features, *May*, 495

MALABSORPTION
  methionine, syndrome of, *May*, 473–4
  tryptophan, *May*, 477
Maladie de Roger, *Feb.*, 160
Malformations. See *Abnormalities.*
Malnutrition, role in mental retardation, *May*, 479

Marfan's syndrome
genetics, *May*, 340
vs. homocystinuria, *May*, 470
Maternal-fetal-placental interrelations involving steroid hormones, *Feb.*, **59–73**
Measles immunization, *Feb.*, 81, 98–9
Meat-base formula in hypercalcemia, *May*, 516
Mental deficiency, self-mutilation and choreoathetosis, hyperuricemia with, *May*, 486, 495
Mental retardation
in hypercalcemia, *May*, 509
role of malnutrition in, *May*, 479
Metabolic action of somatotropin, *May*, 444–8
Metabolism. See also under specific substances.
catecholamine, in neuroblastoma, *Feb.*, 9
inborn errors
clinical features, *May*, 494–6
future of studies on, *May*, 493
newer, *May*, **469–501**
Metachromatic leukodystrophy. See under *Leukodystrophy*.
Metanephrine, *Feb.*, 4
Methasone-treated asthmatics, metyrapone test in, *May*, 547, 551
Methicillin
therapeutic use, *May*, 241, 242
in newborn, *May*, 538
Methionine
effect on tryptophan metabolism, *May*, 473
for acidification of urine, *May*, 240
malabsorption syndrome, *May*, 473–4
clinical features, *May*, 494
metabolism in homocystinuria, *May*, 470
Methioninemia, *May*, 472
Methisazone for smallpox, *Feb.*, 91
Metyrapone, *May*, 543
abnormal response to, factors in, *May*, 552
failure to respond to, significance, *May*, 552
test in ACTH-cortisol insufficiency, *May*, 545–6, 548–51
Milk elimination in hypercalcemia, *May*, 516
Mineral metabolism, effect of somatotropin on, *May*, 445–6
Mineralocorticoids, postoperative use in primary hyperaldosteronism, *Feb.*, 51
Mongolism. See *Down's syndrome*.
Mortality, operative
in aortic stenosis, *Feb.*, 126
in atrial septal defect, *Feb.*, 156
in coarctation of aorta, *Feb.*, 136
Mortality, operative (*Continued*)
in endocardial cushion defects, *Feb.*, 176
in patent ductus arteriosus, *Feb.*, 146
in pulmonic stenosis, *Feb.*, 116
in transposition of great vessels, *Feb.*, 206
in transposition of pulmonary veins, *Feb.*, 186
in tricuspid atresia, *Feb.*, 216
in ventricular septal defect, *Feb.*, 166
Murmur, cardiac, in hypercalcemia, *May*, 509, 511
Muscular dystrophy. See under *Dystrophy*.
Mutilation, self-, choreo-athetosis and mental deficiency, hyperuricemia with, *May*, 486, 495

NAFCILLIN (Unipen), therapeutic use, *May*, 243
Nalidixic acid (NegGram)
dosage, *May*, 239
therapeutic use, *May*, 238–9
Necrotizing encephalopathy, lactic acidosis with, *May*, 491, 496
Neural tumors
chronic diarrhea and, *Feb.*, 13
functioning, *Feb.*, **3–18**
Neuroblastoma, *Feb.*, 4–11
catecholamine metabolism, *Feb.*, 9
Nicotinic acid in Hartnup disease, *May*, 477
NegGram. See *Nalidixic acid*.
Neomycin
dosage, *May*, 240
therapeutic use, *May*, 239–40
in newborn, *May*, 536–7
Neonatal pharmacology, *May*, **527–41**. See also *Newborn*.
Nephritis, glomerular, in hemolytic-uremic syndrome, *May*, 301
Nervous system, central, effects of cytomegalovirus infection on, *May*, 283–5
Neural control of pituitary function, *May*, 429, 430
Neuroendocrine regulation of sexual function and growth, *May*, **423–36**
Newborn
drug absorption, *May*, 528–9
drug distribution, *May*, 529–31
drug excretion, *May*, 533–4
drug metabolism, *May*, 531–3
Nitrofurantoin (Furadantin), therapeutic use, *May*, 240
Norepinephrine, *Feb.*, 3, 4
excretion
in neuroblastoma, *Feb.*, 9
in pheochromocytoma, *Feb.*, 15

Norepinephrine (*Continued*)
postoperative use for pheochromocytoma, *Feb.*, 16
Normetanephrine, *Feb.*, 4
excretion in neuroblastoma, *Feb.*, 9
Novobiocin, therapeutic use in newborn, *May*, 537
Nutrition and genetics, interaction of, in timing of growth and development, *May*, **353–79**

OASTHOUSE urine disease, *May*, 473
Ocular. See *Eyes.*
Operable congenital heart disease, *Feb.*, **105–219**
Organ transplantation, *May*, **381–422**
Osteogenesis imperfecta, genetics, *May*, 345
Ostium primum atrial septal defect, *Feb.*, 168
Oxacillin (Prostaphlin)
therapeutic use, *May*, 242
in newborn, *May*, 538

PARENTERAL fluid therapy for chronic diarrhea with neural tumor, *Feb.*, 13
Parents
genetic counseling, *May*, 337–52
height, specific standards, *May*, 357, 358
mating types and progeny, *May*, 340
Patent ductus arteriosus, *Feb.*, 138–47
PBI. See *Iodine, protein-bound.*
Pediatric problems after renal transplantation, *May*, 397–9
Penicillin. See also *Ampicillin; Cloxacillin; Dicloxacillin; Diphenicillin; Nafcillin; Oxacillin.*
therapeutic use, *May*, 240–45
in newborn, *May*, 537–8
Peritoneal dialysis in hemolytic-uremic syndrome, *May*, 306
Pertussis immunization, *Feb.*, 81, 82–4
Pharmacology, neonatal, *May*, **527–41**
clinical implications, *May*, 534–9
Phenotype, *May*, 339
Phentolamine (Regitine), diagnostic use in pheochromocytoma, *Feb.*, 15
Pheochromocytoma, *Feb.*, 13–16
Phosphate metabolism, effect of somatotropin on, *May*, 446
Physical handicap, delinquency due to, *May*, 462–3
Physicians, iatrogenic ACTH-cortisol insufficiency, duration of, *May*, **543–57**
Physicochemical properties of somatotropin, *May*, 442–4
Physiologic response to psychologic stress, *May*, 321–3

Pituitary
dwarfism, somatotropin for, *May*, 449, 450
function, neural control, *May*, 429, 430
PL. See *Lactogen, placental.*
Placenta
transplacental infection, rubella, *May*, 255–8
transport of maternal corticosteroids, *Feb.*, 68–9
Placental-fetal endocrine relations, *Feb.*, 67–9
Placental lactogen, *May*, 449
Placental-maternal-fetal interrelations involving steroid hormones, *Feb.*, **59–73**
Plasma, umbilical cord, steroids in, measurement, *Feb.*, 63–4
Poliomyelitis
immunity, rapidity after vaccination, *Feb.*, 94–5
immunization, *Feb.*, 81, 93–8, 99–102
of unvaccinated, *Feb.*, 95
Poliovirus vaccines, *Feb.*, 93, 99–102
antibody response to, *Feb.*, 94
dosage, *Feb.*, 97–8
ease of administration, *Feb.*, 95
effectiveness, *Feb.*, 95
for prevention of epidemics, *Feb.*, 96
immunity, durable, *Feb.*, 97
resistance to reinfection, *Feb.*, 95
risk, *Feb.*, 100, 101
safety, *Feb.*, 96
Polymyxin B
therapeutic use, *May*, 245, 246
in newborn, *May*, 536
Polymyxin E. See *Colistimethate.*
Polymyxins, therapeutic use, *May*, 245–6
Postoperative care after renal transplantation, *May*, 391
Postvaccinal encephalitis, *Feb.*, 93
Potassium
depletion in hyperaldosteronism, *Feb.*, 49, 50
metabolism, effect of somatotropin on, *May*, 445
preoperative use in primary hyperaldosteronism, *Feb.*, 51
Prednisone
after renal transplantation, *May*, 393
for hypoaldosteronism, *Feb.*, 56
Prednisone-treated asthmatics, metyrapone test in, *May*, 547, 551
Pregnenolone, biosynthesis, *Feb.*, 61
Premature infants, somatotropin for, *May*, 451
Primary reaction to smallpox vaccination, *Feb.*, 91
Procaine chloride for tissue preservation in renal transplantation, *May*, 387

Progesterone, biosynthesis, *Feb.*, 61
Prolinemia, clinical features, *May*, 495
Prostaphlin. See *Oxacillin.*
Proteins. See also *Amino acids.*
  binding of drugs, *May*, 530
  synthesis in growth promotion, *May*, 445
Psychogenic diseases, *May*, 319
Psychologic factors
  and resistance to infectious disease, *May*, 315–35
  in etiology of disease, *May*, 318–20
Psychologic stress. See under *Stress.*
Psychosis, delinquency as manifestation of, *May*, 466–7
Puberty
  precocious, *May*, 424, 425
    etiology, *May*, 426
    mechanism, *May*, 426–7
  pseudoprecocious, *May*, 425
  timing of, *May*, 427
Public health aspects of hypercalcemia, *May*, 522–3
Pulmonary veins, transposition, complete, *Feb.*, 178–87
Pulmonic stenosis, isolated, *Feb.*, 108–17
Pyridoxine deficiency or dependency, *May*, 476

QUERVAIN'S disease, *Feb.*, 20
Quervain's thyroiditis, *Feb.*, 19

RADIATION
  after renal transplantation, *May*, 394
  intrauterine, leukemia due to, *May*, 268–9
  leukemia due to, *May*, 267–70
  partial-body, leukemia due to, *May*, 268
  preconception, leukemia due to, *May*, 269–70
  therapy
    for ganglioneuroblastoma, *Feb.*, 12
    for neuroblastoma, *Feb.*, 9, 10
  whole-body, leukemia due to, *May*, 267–8
Radiotherapy. See *Radiation therapy.*
Radiologic. See *Roentgen.*
Reactions
  Shwartzman, *May*, 302, 303
  to smallpox vaccination, *Feb.*, 91–2
Regitine. See *Phentolamine.*
Rehabilitation after renal transplantation, *May*, 400
Renal. See *Kidneys.*
Retardation
  developmental, delinquency due to, *May*, 461–2
Retardation (*Continued*)
  mental. See *Mental retardation.*
Reticuloendothelial system in hemolytic-uremic syndrome, *May*, 300
Reticuloendotheliosis vs. neuroblastoma, *Feb.*, 7
Reticulum cell sarcoma vs. neuroblastoma, *Feb.*, 7
Retrolental fibroplasia, genetic counseling in, *May*, 347
Riedel's struma, *Feb.*, 20
Riedel's thyroiditis, *Feb.*, 19
Ringer's solution for tissue preservation in renal transplantation, *May*, 387
Roentgen examination
  for neuroblastoma, *Feb.*, 7
  for pheochromocytoma, *Feb.*, 15
  in aortic stenosis, *Feb.*, 122
  in atrial septal defect, *Feb.*, 152
  in coarctation of aorta, *Feb.*, 132
  in endocardial cushion defects, *Feb.*, 172
  in patent ductus arteriosus, *Feb.*, 142
  in pulmonic stenosis, *Feb.*, 112
  in tetralogy of Fallot, *Feb.*, 192
  in transposition of great vessels, *Feb.*, 202
  in transposition of pulmonary veins, *Feb.*, 182
  in tricuspid atresia, *Feb.*, 212
  in ventricular septal defect, *Feb.*, 162
Roentgen findings in hypercalcemia, *May*, 510–11
Rubella, *May*, 251–66
  congenital defects due to, frequency of, *May*, 252
  diagnostic methods, *May*, 252–3
  embryopathy, prophylaxis of, *May*, 260–63
  epidemiology and teratology, *May*, 251–66
  immunization, *May*, 262
  pathogenesis, *May*, 253–5
  risk to fetus, *May*, 251–2
  syndrome, *May*, 251
    expanded, *May*, 258–60
  teratology and epidemiology, *May*, 251–66
  transplacental infection, *May*, 255–8
  vaccines, *May*, 262–3

SABIN vaccine, *Feb.*, 93
Salk vaccine, *Feb.*, 93
Salt, dietary, for hypoaldosteronism, *Feb.*, 56
Sarcoma, reticulum cell, vs. neuroblastoma, *Feb.*, 7
Sarcosine, *May*, 476

Sarcosinemia, clinical features, *May*, 494
Schick test for diphtheria, *Feb.*, 86
Schmidt's syndrome, *Feb.*, 32
Secundum type of atrial septal defect, *Feb.*, 148–57
Self-mutilation, choreo-athetosis and mental deficiency, hyperuricemia with, *May*, 486, 495
Septal defects. See *Atrial Septal defect; Ventricular septal defect.*
Serum calcium in hypercalcemia, *May*, 510
Sex
  differences in behavior, *May*, 377
  incidence of lymphocytic thyroiditis, *Feb.*, 26
  function, neuroendocrine regulation, *May*, 423–36
Sex-linked inheritance, *May*, 342–3
  vs. autosomal inheritance, *May*, 341–3
Shoulder, skeletal development, *May*, 366
Shwartzman reaction, *May*, 302, 303
Skeleton, development
  genetic and nutritional factors, *May*, 360–67
  variability, *May*, 366
Smallpox
  immunization, *Feb.*, 81, 89–93
  vaccination
    complications, *Feb.*, 93
    contraindications to, *Feb.*, 92
    interpretation of response, *Feb.*, 91–2
Sociologic delinquency, *May*, 460–61
Sodium
  metabolism, effect of somatotropin on, *May*, 445
  renal tubular reabsorption, defect in, *Feb.*, 54
Solution, Ringer's, for tissue preservation in renal transplantation, *May*, 387
Somatotropin (HGH; human growth hormone), *May*, 433–5
  and adrenal hormones, *May*, 447–8
  and insulin, *May*, 448
  bioassays, *May*, 440
  clinical experience, *May*, 449–52
  concepts regarding, *May*, 437–57
  effect on mineral metabolism, *May*, 445–6
  for hypoglycemia, *May*, 451–2
  for idiopathic growth failure, *May*, 451
  for premature infants, *May*, 451
  for short stature, *May*, 449–51
  growth-promoting effect, *May*, 444–5
  immunoassays, *May*, 440–42
  immunologic properties, *May*, 442–4
  measurement, *May*, 440–42
  metabolic action, *May*, 444–8
  physicochemical properties, *May*, 442–4
  production, *May*, 437–40
Somatotropin (*Continued*)
  renal effects, *May*, 447
  secretion, *May*, 437–40
  side effects, *May*, 452
  sulfation factor, *May*, 442
Somatotropin-like compounds, *May*, 448–9
Splenectomy with renal transplantation, *May*, 399
Stature, short, somatotropin for, *May*, 449–51
Stenosis
  aortic, congenital, *Feb.*, 118–27
  pulmonic, isolated, *Feb.*, 108–17
Steroid hormones, fetal-placental-maternal interrelations involving, *Feb.*, 59–73
Steroid. See also *Corticosteroids.*
  gonadal, role in growth and sexual function, *May*, 432–3
Streptomycin
  dosage, *May*, 248
  therapeutic use, *May*, 247–8
    in newborn, *May*, 538–9
Stress
  glucocorticoid therapy in, *May*, 555
  psychologic, *May*, 320–21
    physiologic response to, *May*, 321–3
Stressors, *May*, 320
Struma
  lymphomatosa, *Feb.*, 19, 20
  Riedel's, *Feb.*, 20
Subvalvular aortic stenosis, *Feb.*, 119
Subvalvular pulmonic stenosis, *Feb.*, 109
Sulfatide lipidosis. See under *Lipidosis.*
Sulfation factor of somatotropin, *May*, 442
Sulfonamides, therapeutic use, *May*, 246–7
Supravalvular aortic stenosis, *Feb.*, 119
Supravalvular pulmonic stenosis, *Feb.*, 109
Surgery
  for aortic stenosis, *Feb.*, 126
  for atrial septal defect, *Feb.*, 156
  for coarctation of aorta, *Feb.*, 136
  for endocardial cushion defects, *Feb.*, 176
  for ganglioneuroblastoma, *Feb.*, 12
  for ganglioneuroma, *Feb.*, 12
  for neuroblastoma, *Feb.*, 9, 10
  for patent ductus arteriosus, *Feb.*, 146
  for pheochromocytoma, *Feb.*, 16
  for primary hyperaldosteronism, *Feb.*, 51
  for pulmonic stenosis, *Feb.*, 116
  for tetralogy of Fallot, *Feb.*, 196
  for transposition of great vessels, *Feb.*, 206
  for transposition of pulmonary veins, *Feb.*, 186

Surgery (*Continued*)
for tricuspid atresia, *Feb.*, 216
for ventricular septal defect, *Feb.*, 166
Syndrome
adrenogenital. See *Adrenogenital syndrome.*
Bartter's, *Feb.*, 53
blue diaper. See *Blue diaper syndrome.*
Down's, leukemia and, *May*, 272
formiminotransferase deficiency. See *Formiminotransferase deficiency syndrome.*
gray, *May*, 235, 535
hemolytic-uremic. See *Hemolytic-uremic syndrome.*
Hurler's, genetic causes, *May*, 344
Marfan's. See *Marfan's syndrome.*
methionine malabsorption. See under *Methionine.*
rubella. See *Rubella syndrome.*
Schmidt's, *Feb.*, 32

TEETH
development, genetic and nutritional factors, *May*, 367–73
eruption, genetic and nutritional factors in, *May*, 369
missing, genetic and nutritional factors in, *May*, 371, 372
Tego Pen. See *Cloxacillin.*
Tests
histocompatibility, in renal transplantation, *May*, 385–6
metyrapone, in ACTH-cortisol insufficiency, *May*, 545–6, 548–51
Schick, for diphtheria, *Feb.*, 86
Tetanus
antitoxin, *Feb.*, 87, 88
gamma globulin, *Feb.*, 88, 89
immunization, *Feb.*, 81, 86–9
toxoid, *Feb.*, 87, 88
Tetracycline
dosage, *May*, 249
therapeutic use, *May*, 248–9
in newborn, *May*, 539
Tetralogy of Fallot, *Feb.*, 188–97
Theory, clonal selection, *Feb.*, 23
Therapy
fluid, parenteral, for chronic diarrhea with neural tumor, *Feb.*, 13
radiation. See *Radiation therapy.*
Thrombocytopenia in hemolytic-uremic syndrome, *May*, 299, 300
Thrombosis, fibrin, of glomerular capillaries in hemolytic-uremic syndrome, *May*, 301
Thymectomy with renal transplantation, *May*, 399
Thymus in thyroid autoimmunity, *Feb.*, 24
Thyroglobulin in thyroid autoimmunity, *Feb.*, 22
Thyroid
antibodies in lymphocytic thyroiditis, *Feb.*, 31
autoantibodies, detection, *Feb.*, 30
autoimmunity in lymphocytic thyroiditis, *Feb.*, 22–5
carcinoma, *Feb.*, 19
for lymphocytic thyroiditis, *Feb.*, 34–8
Hashimoto's disease, *Feb.*, 19, 20, 32
hormone, role in growth and sexual function, *May*, 433
hyperplasia in lymphocytic thyroiditis, *Feb.*, 21
hypothyroidism, *Feb.*, 25
Quervain's disease, *Feb.*, 20
Thyroiditis, *Feb.*, 19
diagnosis and management, *Feb.*, **19–42**
lymphocytic, *Feb.*, 20–38
age and, *Feb.*, 26
biopsy findings, *Feb.*, 31, 32
diabetes mellitus with, *Feb.*, 32
goiter in, *Feb.*, 26–7
heredity in, *Feb.*, 33
sex and, *Feb.*, 26
thyroid autoimmunity in, *Feb.*, 22–5
viruses as cause of, *Feb.*, 33–4
management and diagnosis, *Feb.*, **19–42**
Thyroidosis, *Feb.*, 19
Thyrotoxicosis, *Feb.*, 19
Tissue
preservation in renal transplantation, *May*, 387–8
transfer, mismatched, in organ transplantation, *May*, 383
Tolerance, immunologic, *Feb.*, 22, 23
Toxoid, tetanus, *Feb.*, 87, 88
Transfusion, blood, for anemia in hemolytic-uremic syndrome, *May*, 306
Transplacental infection, rubella, *May*, 255–8
Transplantation
liver. See under *Liver.*
organ, *May*, **381–422**
renal, *May*, 382–405
Transposition
of great vessels, *Feb.*, 198–207
of pulmonary veins, complete, *Feb.*, 178–87
Triamterene for Bartter's syndrome, *Feb.*, 53
Tricuspid atresia, *Feb.*, 208–17
Tryptophan
malabsorption, *May*, 477
metabolism, *May*, 476–9
effect of methionine on, *May*, 473
Tryptophanemia, *May*, 478
Tryptophanuria, congenital, with dwarfism, *May*, 478

Tryptophanuria (*Continued*)
clinical features, *May*, 494
Tubules, renal, reabsorption of sodium, defect in, *Feb.*, 54
Tumors
Ewing's, vs. neuroblastoma, *Feb.*, 7
neural. See *Neural tumors.*
Wilms's, vs. neuroblastoma, *Feb.*, 7
Twins, leukemia in, concordance rates, *May*, 273
Tyrosine metabolism, *May*, 480–83
Tyrosinemia, transient, *May*, 480–81
Tyrosinosis, *May*, 482–3
clinical features, *May*, 495

UMBILICAL cord plasma, steroids in, measurement, *Feb.*, 63–4
Unipen. See *Nafcillin.*
Urine
acidification, *May*, 240
creatinine, in ACTH-cortisol insufficiency, *May*, 545
disease, oasthouse, *May*, 473
17-hydroxycorticosteroids, in ACTH-cortisol insufficiency, *May*, 545–6, 547
Uterus, irradiation, leukemia due to, *May*, 268–9

VACCINATION. See also *Immunity.*
sites for, *Feb.*, 82
smallpox. See under *Smallpox.*
Vaccines
combined, *Feb.*, 80
measles, *Feb.*, 99
poliovirus. See *Poliovirus vaccine.*
rubella, *May*, 262–3
Vaccinia, *Feb.*, 93
gamma globulin for, *Feb.*, 92
Vaccinoid reaction to smallpox vaccination, *Feb.*, 91
Valvular aortic stenosis, *Feb.*, 119
Valvular pulmonic stenosis, *Feb.*, 109
Veins, pulmonary, transposition of, complete, *Feb.*, 178–87
Ventricular septal defect, *Feb.*, 158–67
Vessels. See *Blood vessels.*
Viruses
cytomegaloviruses, *May*, 279
biological properties, *May*, 281–2
infection, *May*, 279–93
acquired, *May*, 286–8
central nervous system effects, *May*, 283–5
clinical manifestations, *May*, 285–6
diagnosis, *May*, 288–90
differential diagnosis, *May*, 288
incidence, *May*, 282–3
transmission, *May*, 283
treatment, *May*, 290–91
nonhuman, *May*, 281
physical-chemical properties, *May*, 281–2
properties, *May*, 281–2
ultrastructure, *May*, 282
exanthems, glucocorticoid therapy during, *May*, 555
leukemia due to, *May*, 270–72
lymphocytic thyroiditis due to, *Feb.*, 33–4
Vitamin D
allowances, *May*, 522
elimination in hypercalcemia, *May*, 516
in pathogenesis of hypercalcemia, *May*, 517, 518, 519, 520
VMA, *Feb.*, 4
excretion in neuroblastoma, *Feb.*, 9

WEIGHT, parent-child correlations, *May*, 359
Wilms's tumor vs. neuroblastoma, *Feb.*, 7
Wounds, tetanus prophylaxis, *Feb.*, 88

X-RAY. See *Roentgen.*